跳至主要内容
临床试验/NCT00325143
NCT00325143已完成3 期

Assess Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Admnd at 3 & 4 Mths & DTPa-HBV-IPV/Hib Vaccine Admnd at 5 Mths, Followed by DTPa-IPV/Hib Vaccine at 18 Mths in Infants Who Received hepatitisB Vaccine at Birth & at One Month of Age

GlaxoSmithKline4 个研究点 分布在 1 个国家目标入组 702 人开始时间: 2003年12月1日最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
入组人数
702
试验地点
4
主要终点
Number of Subjects Reporting Any Solicited Local Symptoms

研究概览

简要总结

To assess the safety and reactogenicity of the DTPa-HBV-IPV/Hib vaccine and DTPa-IPV/Hib vaccine. This DTPa-IPV/Hib vaccine given at 3 and 4 months of age is co-administered with GSK Biologicals' rotavirus vaccine or Placebo. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

详细描述

Single group study. Subjects in GSK Biologicals' rotavirus study (Rota-028) in Singapore will be enrolled in this study.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
11 Weeks 至 17 Weeks(Child)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Infanrix Hexa Group

Experimental

Healthy male or female subjects between and including 11 to 17 weeks of age, who were previously vaccinated with Rotarix™ in study 444563/028 (NCT00197210), additionally received 2 doses of Infanrix™-IPV/Hib vaccine (at 3 and 4 months of age), 2 doses of Rotarix™ vaccine (at 2 and 4 months of age) and one dose of Infanrix Hexa™ vaccine (at 5 months of age) as a primary vaccination course, followed by administration of a booster dose of Infanrix™-IPV/Hib vaccine (at 18 months of age). The Infanrix™-IPV/Hib and Infanrix Hexa™ vaccines were administered intramuscularly into the right antero-lateral thigh, while the Rotarix™ vaccine was given orally.

干预措施: DTPa-HBV-IPV/Hib (Biological)

Infanrix Hexa Group

Experimental

Healthy male or female subjects between and including 11 to 17 weeks of age, who were previously vaccinated with Rotarix™ in study 444563/028 (NCT00197210), additionally received 2 doses of Infanrix™-IPV/Hib vaccine (at 3 and 4 months of age), 2 doses of Rotarix™ vaccine (at 2 and 4 months of age) and one dose of Infanrix Hexa™ vaccine (at 5 months of age) as a primary vaccination course, followed by administration of a booster dose of Infanrix™-IPV/Hib vaccine (at 18 months of age). The Infanrix™-IPV/Hib and Infanrix Hexa™ vaccines were administered intramuscularly into the right antero-lateral thigh, while the Rotarix™ vaccine was given orally.

干预措施: DTPa-IPV/Hib vaccine (Biological)

结局指标

主要结局

Number of Subjects Reporting Any Solicited Local Symptoms

时间窗: During the 4-day (Days 0-3) post-vaccination period following each dose and across doses

Assessed solicited local and general symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade.

Number of Subjects Reporting Any Solicited General Symptoms

时间窗: During the 4-day (Days 0-3) post-vaccination period following each dose and across doses

Assessed solicited general symptoms were drowsiness, fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\], irritability and loss of appetite. Any = occurrence of the symptom regardless of intensity grade.

次要结局

  • Number of Subjects Reporting Any Serious Adverse Events (SAEs)(During the entire study period (from Month 0 up to Month 21))
  • Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)(During the 31-day (Days 0-30) post-vaccination period)
  • Number of Subjects Reporting Any Large Swelling Reactions(At Month 15, post-booster dose)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验

已完成
3 期
DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese InfantsPoliomyelitisBacterial MeningitisDiphtheriaTetanusPertussis
NCT02274285Sanofi Pasteur, a Sanofi Company424
进行中(未招募)
1 期
Study to Assess the Immune Response and the Safety Profile of DTaP-IPVHB- PRP~T Combined Vaccine Given Concomitantly or Sequentially with 4CMenB Vaccine in Italian InfantsHaemophilus influenzae type b immunisationMedDRA version: 21.1Level: LLTClassification code 10054181Term: Hepatitis B immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: PTClassification code 10069533Term: Haemophilus influenzae type b immunisationSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2019-002585-12-ITSANOFI PASTEUR396
进行中(未招募)
1 期
Study to Assess the Immune Response and the Safety Profile of DTaP-IPV-HB-PRP~T Combined Vaccine Given Concomitantly or Sequentially with 4CMenB Vaccine in Italian and Finnish InfantsHaemophilus influenzae type b immunisationMedDRA version: 21.1Level: LLTClassification code 10054181Term: Hepatitis B immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 21.1Level: PTClassification code 10069533Term: Haemophilus influenzae type b immunisationSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2019-002585-12-FISanofi Pasteur200
已完成
3 期
Vaccination of Children Following Allogeneic Stem Cell TransplantationAllogeneic Haematopoietic Stem Cell Transplantation
NCT00169728Heinrich-Heine University, Duesseldorf53
已完成
3 期
Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.Acellular PertussisPoliomyelitisTetanusDiphtheria
NCT00871000GlaxoSmithKline303